10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Recurrent or metastatic nasopharyngeal carcinoma is nasopharyngeal cancer that has come back after radiotherapy or spread to the bones, liver or lungs. Gemcitabine with cisplatin is the chemotherapy backbone, adding a PD-1 antibody such as toripalimab in JUPITER-02 and later trials lengthened survival and became standard, and local recurrence is treated with endoscopic surgery or re-irradiation.
Nasopharyngeal carcinoma recurs in two ways that are treated differently. Local or regional recurrence after radiotherapy, in the nasopharynx or neck, is potentially curable: endoscopic nasopharyngectomy, shown in a Chinese randomised trial (Lancet Oncology 2021) to give better survival and fewer complications than re-irradiation for resectable recurrence, neck dissection for nodal relapse, and hyperfractionated intensity-modulated re-irradiation, which in a further randomised trial (Lancet 2023) reduced the severe late toxicity of a second course of radiotherapy. Distant metastases, most often to bone, liver and lung, are incurable in most patients, although people who present with metastases gain from locoregional radiotherapy added to chemotherapy: in a 126-patient Chinese phase 3 (JAMA Oncology 2020) two-year survival was 76 percent with it and 55 percent with chemotherapy alone.
Systemic therapy for metastatic disease was standardised by the GEM20110714 trial (Lancet 2016), in which gemcitabine and cisplatin beat fluorouracil and cisplatin on progression-free survival (7.0 against 5.6 months) and, in the final analysis (2021), overall survival (median 22.1 against 18.6 months). Because EBV-driven tumours are inflamed and PD-L1-rich, PD-1 antibodies were tested next, almost entirely by Chinese companies and investigators: JUPITER-02 (Nature Medicine 2021, JAMA 2023) added toripalimab to gemcitabine-cisplatin in 289 patients and lengthened median progression-free survival from 8.0 to 11.7 months at the interim analysis and from 8.2 to 21.4 months at the final one, with longer overall survival (hazard ratio 0.63), leading to approval in China in 2021 and in the United States in October 2023, the first drug the FDA approved for nasopharyngeal carcinoma. CAPTAIN-1st (camrelizumab, Lancet Oncology 2021) lengthened median progression-free survival from 6.9 to 9.7 months and, at five years, median overall survival from 26.6 to 34.5 months; RATIONALE-309 (tislelizumab) lengthened progression-free survival, but its overall survival difference was not statistically significant at three years (hazard ratio 0.73, 95 percent confidence interval 0.51 to 1.05), and the United States label for tislelizumab does not include this cancer. Penpulimab with gemcitabine and cisplatin or carboplatin was approved in the United States in April 2025 for non-keratinising disease. PD-1 antibodies alone are used after platinum failure (nivolumab, pembrolizumab, camrelizumab and toripalimab all have phase 2 data), and later lines include gemcitabine-based or taxane-based chemotherapy, capecitabine and the anti-EGFR antibody nimotuzumab in China. Antibody-drug conjugates have begun to reach practice in China: the EGFR-directed becotatug vedotin (MRG003) was approved there in October 2025 for disease that has failed at least two lines of chemotherapy and a PD-1 or PD-L1 antibody, and the EGFR-HER3 bispecific izalontamab brengitecan (BL-B01D1) doubled the response rate against chemotherapy in a 386-patient phase 3 (54.6 against 27.0 percent, Lancet 2025, with survival data not yet mature) and was approved there in 2026; the B7-H3-directed YL201 is in phase 3 (TAISHAN-301). EBV-specific T-cell therapy has not held up: the 330-patient VANCE phase 3 found no survival gain from adding it to chemotherapy (median 25.0 against 24.9 months, Annals of Oncology 2024). Plasma EBV DNA tracks response, and locoregional radiotherapy for de novo metastatic disease with a good chemotherapy response is now guideline-endorsed.
| Setting | Approach | Guideline |
|---|---|---|
| Resectable local recurrence | Endoscopic nasopharyngectomy (better survival and fewer complications than re-irradiation in a randomised trial); neck dissection for nodal recurrence. | not mapped |
| Unresectable local recurrence | Hyperfractionated intensity-modulated re-irradiation or proton therapy with careful dose constraints; systemic therapy where re-irradiation is unsafe. | not mapped |
| Metastatic disease, first line | Gemcitabine and cisplatin with a PD-1 antibody (toripalimab, JUPITER-02; camrelizumab, CAPTAIN-1st; tislelizumab, RATIONALE-309; penpulimab; in the United States only toripalimab and penpulimab are licensed for this cancer), then PD-1 maintenance; locoregional radiotherapy to the primary in patients with a good response. | not mapped |
| After platinum and PD-1 therapy | Gemcitabine, taxane or capecitabine-based chemotherapy; nivolumab or pembrolizumab if no prior PD-1 antibody; antibody-drug conjugates (becotatug vedotin, MRG003, and izalontamab brengitecan, BL-B01D1, both approved in China only; YL201 in trials). | not mapped |
| Oligometastatic disease | Stereotactic radiotherapy or resection of limited metastases with systemic therapy. | not mapped |